Evaluating Immune Cell Receptors in Lupus Patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study investigates the expression of the neonatal Fc receptor (FcRn) in Natural Killer T Cells and monocytes in patients with systemic lupus erythematosus. It aims to compare the receptor expression in active or newly diagnosed lupus patients against those with inactive disease. By understanding the role of FcRn and other Fc gamma receptors in the immune response, the study seeks to clarify their involvement in the pathophysiology of lupus. Blood samples will be collected for analysis to assess the relationship between receptor expression and disease activity.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age ≥ 18 years
* Diagnosis of definite systemic lupus which may be associated with secondary antiphospholipid syndrome and/or secondary Gougerot-Sjögren's
* Lupus patient, newly diagnosed or known, untreated or in relapse
* Lupus patient considered stable by the treating practitioner
* Requiring blood sampling for follow-up

Exclusion Criteria:

* Main autoimmune disease other than lupus
* Patient under legal protection, guardianship or curators
* Opposition to data processing

Where it's running

• University Hospital
  Tours, France Recruiting

Study contacts

• Principal investigator: Yanis RAMDANI — CHRU de Tours
• Study coordinator: Yanis RAMDANI
• Email: yanis.ramdani@univ-tours.fr
• Phone: 0234378919

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Effects of anifrolumab on arterial inflammation in SLE patients

  This study tests whether anifrolumab can reduce blood vessel inflammation in people with active systemic lupus erythematosus.

  Recruiting University of Cambridge · Cambridge, Cambridgeshire · NCT07913919

• Home urine testing for people with lupus

  Participants with lupus will try weekly home urine tests in addition to usual care to see if this helps monitor kidney health over a year.

  Recruiting NYU Langone Health · New York, New York · NCT07823478

• CR-402 treatment for refractory autoimmune disease

  This study tests CRT-402, a CD19-targeted CAR-T therapy, in adults with active, treatment-resistant autoimmune diseases like SLE, systemic sclerosis, and inflammatory myopathy to see if it is safe and capable of helping control disease.

  Recruiting Phase 1/2 Myeloid Therapeutics · Nedlands, Western Australia · NCT07778446

• ATG-201 in adults with autoimmune diseases

  This early, open-label study tests ATG-201 in adults with autoimmune diseases to see if it is safe and tolerable, and to get initial clues about how the body handles the drug and its effects.

  Recruiting Phase 1 Antengene Corporation · Bengbu, Anhui and 21 other locations · NCT07732309

• Biomarker tests in adults with lupus to see how kidney disease changes over time

  Researchers will follow adults with lupus to see if blood and urine biomarkers can predict kidney involvement, flares, and treatment responses during routine care.

  Recruiting Oslo University Hospital · Oslo, Oslo · NCT07666711

• Sirolimus added to standard therapy for adults with SLE-associated immune thrombocytopenia

  This trial tests whether adding sirolimus to usual treatment helps adults with SLE-related immune thrombocytopenia see their platelet counts improve.

  Recruiting Phase 2/3 Chinese SLE Treatment And Research Group · Beijing, Beijing Municipality · NCT07657793

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.